WHO adds to pressure on companies to cut cost of Hepatitis C drugs

|By:, SA News Editor

The World Health Organization has joined those calling for a reduction in the prices of new Hepatitis C drugs, such as Gilead's (GILD) Sovaldi and Jonhson & Johnson's (JNJ) Olysio. In the U.S., Sovaldi costs $84,000 and Olysio $66,000.

Around 150M people worldwide suffer from chronic hepatitis C, but the vast majority live in poor countries that can't afford the price.

Pharmaceutical companies could follow the model that was used to bring the cost of HIV treatments down in the developing world, and Gilead is already giving Egypt a 99% discount on Sovaldi.